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Glycoprotein B (gB) is conserved among the herpesvirus family which infects a broad range of species. To investigate
the functional homology of human a-herpesviruses, b-herpesviruses, and g-herpesviruses gB proteins, complementation
studies were performed with gB genes from each subfamily member using EBV gp110 (EBV gB homologue) and HSV-1 gB
null mutants. Neither the a-herpesvirus HSV-1 gB gene nor the b-herpesvirus HCMV gB gene were able to complement
the gp110 null mutant. Conversely, neither the b-herpesvirus HCMV gB or the g-herpesvirus EBV gp110 gene were able
to complement HSV-1 gB null mutants. To further investigate functional domains of EBV gp110 and HSV-1 gB, gB-gp110
chimeric proteins were constructed. Surprisingly, none of the chimeric proteins were able to complement either HSV-1 gB
null mutants or EBV gp110 null mutants. These results demonstrate that there is not sufficient functional homology between
the different gBs to allow complementation in other subfamily members of the herpesvirus family. q 1997 Academic Press
INTRODUCTION infected cell (Hutt-Fletcher, 1995; Roizman et al., 1994;
Spear, 1993a,b). In the a-herpesvirus HSV-1, five glyco-
Epstein–Barr virus (EBV) is one of eight human her- proteins have been identified that play important roles in
pesviruses which latently infect humans (Roizman et al., viral binding and entry into cells. Binding of virus to cells
1994). The human herpesvirus are organized into three is the primary role of gC, although gB may have an acces-
subfamilies depending on biological characteristics and sory role (Herold et al., 1994, 1991; Little et al., 1981;
evolutionary relatedness. The three human a-herpesvi- Shieh et al., 1992; Svennerholm et al., 1991; WuDunn
ruses, herpes simplex virus type 1 (HSV-1), HSV-2, and and Spear, 1989). Fusion of the virion envelope with the
varicella zoster (VZV) are characterized by their rapid plasma membrane requires the actions of gB, gD, and
reproductive cycle and capacity to establish latent infec- the gH/gL complex (Cai et al., 1987; Desai et al., 1988;
tions in sensory ganglia (Roizman et al., 1994). The three Forrester et al., 1992; Ligas and Johnson, 1988; Little et
human b-herpesviruses, human cytomegalovirus al., 1981; Roop et al., 1993; Sarmiento et al., 1979).
(HCMV), human herpesvirus 6 (HHV6), and HHV7, typi- When compared to their homologues among the a-
cally have a long reproductive cycle and remain latent herpesviruses, the nucleotide and amino acid sequences
in a variety of tissues (Roizman et al., 1994). The two of the nine glycopropteins known to be encoded by the
human g-herpesviruses include the recently idenitified human g-herpesvirus EBV range from substantially con-
HHV8 and Epstein–Barr virus, both of which are distin- served to virtually unrelated (Hutt-Fletcher, 1995). For in-
guished by their latent infection of lymphoblastoid cell stance, a gH/gL complex homologue (gp85/gp25) is pres-
lines either of T or B cell origin (Roizman et al., 1994). ent in EBV-infected cells, but it contains a third glycopro-
Although strategies to establish latent infection vary for tein, gp42, which has no known relatives in the other
each herpesvirus subfamily, many features of productive human herpesviruses (Haddad and Hutt-Fletcher, 1989;
infection are conserved between the different members. Heineman et al., 1988; Hutt-Fletcher, 1995; Li et al., 1995;
All herpesviruses use membrane glycoproteins in a vari- Miller and Hutt-Fletcher, 1988, 1992). This additional
ety of important processes during replication. These pro- component is important for infection of B lymphocytes,
cesses include specific binding of the virion to the cell but not epithelial cells (Li et al., 1995). Reflecting its spe-
surface, fusion of the viral envelope with the plasma cialized cellular niche in B lymphocytes, EBV binding to
membrane, virion assembly, and virion egress from the the cell surface utilizes a specific interaction between
the type two complement receptor, CR2 (CD21), and
gp350/220, which has no known herpesvirus homologue1 Present address: Catholic Research Institutes of Medical Science,
(Li et al., 1995; Nemerow et al., 1989, 1987; Tanner et al.,Catholic University, 505 Banpo-dong, Seocho-ku, Seoul, 137-701.
1987, 1988).2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (312)-503-1339. E-mail: r-longnecker@nwu.edu. All herpesviruses examined to date contain a gB ho-
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mologue (Goltz et al., 1994; Pereira, 1994; Ross et al., ment mutations in members of other subfamilies. In this
study, the ability of the a-herpesvirus HSV-1 gB and the1989). The positions of cysteine residues is conserved
in the herpesvirus gBs and there is considerable amino b-herpesvirus HCMV gB to complement a g-herpesvirus
EBV gp110 null mutant was tested. In reciprocal experi-acid homology in the carboxy-terminal portion of the pro-
teins from the different herpesviruses. In contrast, the ments, the ability of EBV gp110 and HCMV gB to comple-
ment an HSV-1 gB null mutant was examined. To furtheramino-terminal portions of these molecules exhibit sub-
stantial diversity at the level of amino acid homology. analyze functional domains of gB and gp110, gB-gp110
chimeric proteins were constructed. The analysis per-Finally, on a structural level, the gB proteins can be sepa-
rated into two groups based on the presence or absence formed in this study indicates that there is not sufficient
homology between the different subfamily gBs to allowof a furin-mediated, proteolytic cleavage site (Eberle and
Black, 1993; Pereira, 1994). For example, the EBV and complementation in other members of the herpesvirus
family.HSV gB proteins are not cleaved during biosynthesis
while the HCMV gB is cleaved into two disulfide linked
fragments (Pereira, 1994; Spaete et al., 1988). In addition, RESULTS
notable differences exist with regards to the abundance
Expression of HCMV gB and HSV-1 gB in
of the proteins in the virion particle. Remarkably, the EBV
EBV(gp1100)/ LCLs
gB, gp110, is a minor component of the virion, and there
are no appreciable amounts of gp110 in the plasma To investigate the ability of HSV-1 gB and HCMV gB
to complement a gp110 null mutation, expression of bothmembrane of infected cells; rather gp110 localizes pre-
dominantly to the inner and outer membranes of the nu- gBs were evaluated following transfection into the
EBV(gp1100)/ LCL M.2 in which gp110 is not expressedcleus and the endoplasmic reticulum (ER) (Emini et al.,
1987; Gong and Kieff, 1990; Gong et al., 1987; Qualtiere due to insertion of a cassette expressing the hygromycin
phosphotransferase gene driven by the simian virus 40and Pearson, 1979). In contrast, the HCMV gB protein is
by far the most abundant constituent of the virion enve- early promoter (SVHYG) (Herrold et al., 1996). M.2 LCLs
were transfected with pSG5, pHCMV-gB, pSVgp110, andlope (Britt, 1984; Gretch et al., 1988), whereas the abun-
dance of the a-herpesvirus gB proteins is intermediate pHSV-gB as previously described (Herrold et al., 1996).
The HCMV gB expression vector, pHCMV-gB, consiststo that of EBV and HCMV (Pereira, 1994).
Certainly, all gB proteins examined to date, including of a 2.8-kb HCMV fragment containing the entire HCMV
gB coding region cloned into the HindIII and XbaI siteEBV and HSV, are key replication components as evi-
denced by the lack of growth of gB null strains in the of pRC/CMV (Invitrogen, San Diego, CA). The HSV-1 gB
expression vector was constructed by cloning a BalI toabsence of complementation (Cai et al., 1987; Herrold et
al., 1996). Functional homology between different animal KpnI fragment from the HSV-1(KOS) genome which con-
tains the entire gB coding domain into a derivative ofa-herpesvirus gBs was demonstrated by the construction
of viral recombinants and complementation of gB null pSG5 (Stratagene, La Jolla, CA). Following transfection,
cells were radiolableled with [35S]methionine and cys-mutants (Eberle et al., 1997; Kopp and Mettenleiter, 1992;
Mettenleiter and Spear, 1994; Miethke et al., 1995; Misra teine, lysed in 1% NP-40 and immunoprecipitated with
mouse monoclonal antibodies against the appropriateand Blewett, 1991; Rauh et al., 1991). Analysis of HSV-1
recombinants containing gBs of both HSV-1 and bovine protein depending on the transfected expression con-
struct (Herrold et al., 1996; Lee and Longnecker, 1997).herpesvirus 1 (BHV-1) have indicated that BHV-1 gB may
function in HSV-1 infectivity (Misra and Blewett, 1991). Immunoprecipitated proteins were separated by denatur-
ing 8% SDS–polyacrylamide gels. Following electropho-HSV-1 containing null mutations in gB can also be com-
plemented by PrV gB (Mettenleiter and Spear, 1994). In resis, the gels were fixed, dried, and immunoprecipitated
proteins were visualized by autoradiography. As ex-contrast, PrV gB mutants cannot be complemented by
HSV-1 gB (Mettenleiter and Spear, 1994). Pseudorabies pected, both the precursor form and mature form of
HCMV gB were immunoprecipitated from pHCMV-gB-virus (PrV) containing a gB null mutation can be comple-
mented by BHV-1 gB either by growth on a BHV-1 gB transfected cells when immunoprecipitated with the
HCMV gB-specific monoclonal antibody 27-78 (Britt,expressing cell line or by insertion of BHV-1 gB into the
PrV viral genome (Kopp and Mettenleiter, 1992; Rauh et 1984) (Fig. 1A, lane 2, P and M). Interestingly, the HCMV
gB was not proteolytically cleaved. Many gB homologuesal., 1991). In contrast a BHV-1 gB null mutant is unable
to be complemented by PrV gB (Miethke et al., 1995). undergo proteolytic cleavage generating disulfide-linked
products (Pereira, 1994a). Failure to cleave PRV, BHV-1,Using chimeric gB proteins between PrV gB and BHV-1
gB, the carboxy-terminal portion of BHV-1 gB was demon- or CMV gB does not affect virion infectivity (Blewett and
Misra, 1991; Brucher et al., 1990; Kopp et al., 1994; Qadristrated to be important for BHV-1 gB-specific function
(Miethke et al., 1995). et al., 1992; Spaete et al., 1990; Tugizov et al., 1995). As
had been previously observed, gp110 was detected inThere has been no investigation of the ability of the
different human herpesvirus subfamily gBs to comple- pSVgp110-transfected cells when lysates were immuno-
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TABLE 1precipitated with the gp110-specific monoclonal antibody
L2 (Chemicon, Temecula, CA) (Fig. 1A, lane 3) (Herrold Transformants Obtained by Passage of EBV(gp110/)/ and
et al., 1996). Both the precursor form and mature form of EBV(gp1100)/ LCLs by Complementation with HSV-1 gB a
HSV-1 gB was also detected in pHSV-gB-transfected
Experimental group Cell line pSVgp110 pHSV-gBcells when immunoprecipitated with the HSV-1 gB-spe-
cific monoclonal antibody II105-1 (Para et al., 1985) (Fig.
EBV(gp110/)/ LCLs LCL1 1 0
1A, lane 4, P and M). No immunoprecipitated proteins (Cocultivation) 4 3
were detected in vector control-transfected cells when 6 0
0 0immunoprecipitated with the CMV gB-specific mono-
9 9clonal antibody 27-78 except for background bands pres-
2 1ent in all immunoprecipitations (Fig. 1A, lane 1).
3 3
LCL10 17 4
Complementation analysis of EBV(gp1100)/ LCLs Total 42 20
with HSV-1 gB and HCMV gB
EBV(gp1100)/ LCLs M.2 3 0
(Cocultivation) 1 0To determine if HSV-1 gB or HCMV gB could comple-
3 0ment the gp110 null mutation present in EBV(gp1100)/
3 0LCLs, complementation experiments were performed as
1 0
previously described (Herrold et al., 1996; Lee and Long- 5 0
necker, 1997). EBV(gp110/)EBV/ LCLs (LCL1 and 2 0
6.16 1 0LCL10) and EBV(gp1100)/ LCLs (M.2, 6.16, and KC.1)
1 0were transfected with pSVgp110, pHSV-gB, and pHCMV-
1 0
1 0
1 0
1 0
KC.1 5 0
2 0
12 0
11 0
3 0
Total 57 0
EBV(gp110/)/ LCLs LCL1 0 0
(Cell free) 5 4
1 0
1 0
LCL10 0 1
2 0
Total 9 5
EBV(gp1100)/ LCLs M.2 1 0
(Cell free) Total 1 0
a Cells were transfected with the indicated plasmids. Three to five
days posttransfection, primary human B lymphocytes were cocultivated
with gamma-irradiated transfected cells or infected with cell-free virus.
Wells positive for EBV transformation were counted 6–8 weeks after
the infection. One 96-well plate was used for each transfection. Each
FIG. 1. Expression of CMV gB, EBV gp110, HSV-1 gB, and gB-gp110 line represents a different experiment. Totals represent the sum of the
chimeric proteins in the EBV(gp110-)/ LCL M2. M.2 cells were trans- number of clones that emerged for each experimental group as indi-
fected with the indicated plasmids and labeled with [35S]methionine- cated. The presence of the SVHYG insertion in the newly obtained
cysteine (Lee and Longnecker, 1997). Twenty-four hours after transfec- LCLs from EBV(gp1100)/ LCLs was verified by PCR (data not shown)
tion, cells were washed with phosphate-buffered saline (PBS) and lysed as previously described (Herrold et al., 1996). Control amplifications for
in 1% NP-40 lysis buffer (Lee and Longnecker, 1997). Following centrifu- the EBV genome using primers specific for the BHRF1 gene (Marchini et
gation, the cleared lysates were immunoprecipitated with the mono- al., 1991) as expected were positive for all EBV/ LCLs (data not shown).
clonal antibody 27-78 reactive with HCMV gB (A, lanes 1 and 2), L2
reactive with EBV gp110 (A, lane 3), or II105-1 reactive with HSV-1
gB (A, lane 4, and B, lanes 1 – 4). Immunoprecipitated proteins from gB (Tables 1 and 2). To induce lytic replication, the LCLs
equivalent cell numbers were loaded in each lane and separated by were also transfected with pSVNaeZ (Swaminathan et
denaturing 8% SDS–PAGE (Herrold et al., 1996; Lee and Longnecker, al., 1991) and cultured for 3 to 5 days following transfec-
1997). Gels were dried and subjected to autoradiography. Molecular
tion with media containing 20 ng/ml TPA. Virus produc-weight standards are indicated at the left in kilodaltons. The location
tion was monitored by culturing freshly isolated B lym-of the precursor (P) and mature (M) forms of the expressed glycopro-
teins are indicated. phocytes with lethal gamma-irradiated transfected LCLs
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TABLE 2 virus was detected only when the EBV(gp1100)/ LCLs
were transfected with the gp110 expression vector (Ta-Transformants Obtained by Passage of EBV(gp110/)/ and
bles 1 and 2, pSVgp110). No complementation was ob-EBV(gp1100)/ LCLs by Complementation with HCMV gB a
served when the HSV-1 gB expression vector (pHSV-gB)
Experimental group Cell line pSVgp110 pHCMV-gB or the HCMV gB expression vector (pHCMV-gB) was
used in the transfections, demonstrating that neither
EBV(gp110/)/ LCLs LCL1 9 10
HSV-1 gB nor HCMV gB was able to complement the(Cocultivation) 10 13
gp110 defect in EBV(gp1100)/ LCLs (Tables 1 and 2).24 15
5 54
6 6 Construction of HSV-1 gB and EBV gp110 chimeric
5 3 proteins
LCL10 22 23
31 29 Since HSV-1 gB was unable to complement EBV-
26 22 (gp1100)/ LCLs, chimeric proteins between HSV-1 gB
22 15 and EBV gp110 were constructed. Prior experimentation
95 93
had demonstrated a potential novel role of the gp110 tailTotal 255 283
domain in assembly of infectious virions during EBV lytic
EBV(gp1100)/ LCLs M.2 2 0 replication (Lee and Longnecker, 1997). To determine if
(Cocultivation) 5 0
the gp110 tail domain was sufficient to confer the ability1 0
of HSV-1 gB to complement the gp110 null mutation,KC.1 9 0
12 0 two chimeric proteins were constructed (Fig. 2). The first
17 0 chimeric construct, pgBHSV(1-722)EBV(680-857), was
33 0 made by creating unique Tth111 I and BglII sites by PCR
5 0
within gp110 and cloning the resulting fragment into5 0
Tth111 I and BglII-digested pHSV-gB. This construct con-Total 89 0
tains amino acids 1 to 722 of HSV-1 gB fused to amino
EBV(gp110/)/ LCLs LCL1 2 0
acids 680 to 857 of EBV gp110 and contains the three(Cell free) 3 5
hyrophobic domains of EBV gp110 and the entire gp11010 2
LCL10 89 88
85 87
90 77
Total 279 259
EBV(gp1100)/ LCLs M.2 3 0
(Cell free) 6 0
KC.1 5 0
3 0
6 0
Total 23 0
a Cells were transfected with the indicated plasmids. Three to five
days posttransfection, primary human B lymphocytes were cocultivated
with gamma-irradiated transfected cells or infected with cell-free virus.
Wells positive for EBV transformation were counted 6–8 weeks after
the infection. One 96-well plate was used for each transfection. Each
line represents a different experiment. Totals represent the sum of the
number of clones that emerged for each experimental group as indi-
cated. The presence of the SVHYG insertion in the newly obtained
LCLs from EBV(gp1100)/ LCLs was verified by PCR (data not shown)
as previously described (Herrold et al,. 1996). Control amplifications for
the EBV genome using primers specific for the BHRF1 gene (Marchini et
al., 1991) as expected were positive for all EBV/ LCLs (data not shown).
FIG. 2. Schematic representation of EBV gp110, HSV-1 gB, and the
or cell-free virus preparations (Herrold et al., 1996; Lee gB-gp110 chimeric proteins constructed in these studies. The EBV
gp110 coding domain is represented by open boxes with hatchedand Longnecker, 1997; Marchini et al., 1991). Six to eight
boxes indicating the three hydrophobic domains contained within theweeks postinfection, transformed LCLs were identified
gp110 coding domain. The HSV-1 gB coding domain is represented byand expanded. Virus from EBV(gp110/)/ LCLs virus
shaded boxes, with solid boxes indicating the three hydrophobic do-
transformed primary B lymphocytes and transformation mains contained within the gB coding domain. Numbers on top of the
was not affected by transfection with any of the expres- boxes indicate the gp110 amino acid number while numbers on the
bottom indicate the gB amino acid number.sion vectors (Tables 1 and 2). In contrast, transforming
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tail domain. The second chimeric construct, pgBHSV(1- lum (ER) and nuclear membrane (Fig. 3A). In contrast, HSV-
1 gB was detected using monoclonal antibody II105-1 in788)EBV(746-857), was made by creating unique FseI
and BglII sites by PCR within the gp110 coding domain both fixed and live cell preparations, indicating that gB
is found in both intracellular membranes and the plasmaand cloning the resulting fragment into FseI and BglII-
digested pHSV-gB. This chimeric construct includes membrane (Fig. 3B, pSVHSV-1 gB). Interestingly, both of
the gB-gp110 chimeric proteins were detected only in fixedamino acids 1 to 788 of HSV-1 gB fused to amino acids
746 to 857 of EBV gp110 and contains the entire first two cell preparations, indicating retention in intracellular mem-
branes using the gB-specific antibody as was observedhydrophobic domains and two-thirds of the third hy-
drophobic domain of HSV-1 gB with the remaining one- for gp110 (Fig. 3B, pgBHSV(1 – 722)EBV680 – 857 and
pgB(HSV(1–788)EBV(746–857)). These results agree withthird of the final hydrophobic domain and the entire tail
domain of EBV gp110. Both chimeric proteins were fused previous studies (Lee and Longnecker, 1997), indicating
that a domain for nuclear membrane and ER retention iswithin homologous regions of each protein. Integrity of
the chimeric reading frames was confirmed by DNA se- located in the tail domain of gp110 and appears functional
upon transfer to HSV-1 gB. These prior studies had identi-quencing (data not shown).
Expression of the chimeric proteins was confirmed fied a region from amino acid 816 to 841 of the gp110 tail
domain containing four adjacent arginines as essential forby transfection in the EBV(gp1100)/ LCL M.2 followed
by immunoprecipitation of [35S]methionine-cysteine-la- nuclear membrane and ER retention of gp110 (Lee and
Longnecker, 1997). No reactivity was observed in vectorbeled proteins with the HSV-1 gB-specific monoclonal
antibody II105-1 (Fig. 1B). This monoclonal antibody control-transfected cells with the L2 or II105-1 antibodies
(Figs. 3A and 3B, pSG5).has been demonstrated to recognize the ectodomain
of gB and should react equally well with each of the
Complementation analysis of EBV(gp1100)/ LCLschimeric proteins (Para et al., 1985). In pHSV-gB-trans-
with gB-gp110 chimeric proteinsfected LCLs, both the precursor form and mature form
of HSV-1 gB were readily detected (Fig. 1B, lane 1,
To investigate if the chimeric proteins would complement
P and M). In both pgBHSV(1 – 721)EBV(680 – 857) and
EBV(gp1100)/ LCLs, EBV(gp110/)/ LCLs (LCL1 and
pgBHSV(1 – 787)EBV(745 – 857) the appropriate precur-
LCL10) and EBV(gp1100)/ LCLs (M.2 and KC.1) were
sor sized gB-gp110 chimeric protein was detected (Fig.
transfected with pSVgp110, pgBHSV(1–722)EBV(680–857),
1B, lanes 2 and 3, just below HSV-1 gB precursor).
or pgBHSV(1–788)EBV(746–857) as indicated in Table 3.
Both of the gB-gp110 chimeric proteins are five amino
To induce lytic replication, the LCLs were also transfected
acids smaller than the HSV-1 gB. Interestingly, mature
with pSVNaeZ (Swaminathan, Tomkinson, and Kieff, 1991)
forms of the gB-gp110 chimeric proteins were not de-
and cultured for 3 to 5 days following transfection in the
tected (Fig. 1B, lanes 2 and 3), suggesting that the
media containing 20 ng/ml TPA. Virus production was moni-
chimeric proteins had not trafficked through the Golgi.
tored by assessing transforming activity by culturing freshly
In EBV-infected cells undergoing lytic replication, the
isolated primary B lymphocytes with lethally gamma-irradi-
majority of gp110 has only endo H-sensitive high-man-
ated transfected cells or cell-free virus preparations (Her-
nose N-linked oligosaccharides, indicating that the
rold et al., 1996; Lee and Longnecker, 1997). Six to eight
gp110 product has not trafficked though the Golgi
weeks after infection, transformed cells were identified and
(Gong and Kieff, 1990). This high mannose form is anal-
expanded. LCL1 and LCL10 produced infectious virus
ogous to the immature form of HSV-1 gB. HSV-1 gB is
which readily transformed primary B cells and was unaf-
also first synthesized as a high mannose precursor,
fected by transfection with any of the gp110 expression
but in contrast to EBV gp110 is then processed into
vectors as expected (Table 3). In contrast, transforming
the mature form of gB by the addition of complex oligo-
activity was observed from EBV(gp1100)/ LCLs only when
saccharides by trafficking through the Golgi (Johnson
wild-type gp110 was transfected (Table 3). No transforming
and Spear, 1983; Person et al., 1982; Wenske et al.,
activity was observed when either of the gB-gp110 chimeric
1982).
proteins were used in the complementation experiments,
indicating the gp110 tail domain when fused to gB is unable
Intracellular localization of gp110, gB, and the to complement the gp110 null LCLs.
gB-gp110 chimeric proteins
Complementation analysis of HSV-1 gB null virus with
The intracellular localization of gp110, gB, and gB-gp110 EBV gp110, HCMV gB, EBVgp110 tail domain deletion
chimeric proteins was investigated by live cell and fixed cell mutations, and gB-gp110 chimeric proteins
immunofluorescence in BJAB cells following transfection of
the expression constructs (Lee and Longnecker, 1997) (Fig. A previously described transient expression assay
was used to determine the ability of the various glycopro-3). In fixed cell preparations, but not live cell preparations,
gp110 was detected using the monoclonal antibody L2, tein expression constructs to complement the gB defect
in the HSV-1 virus K082 (Cai et al., 1987; Herold et al.,indicating that gp110 is restricted to the endoplasmic reticu-
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FIG. 3. Immunofluorescence microscopy of BJAB cells transfected with glycoprotein expression vectors (Herrold et al., 1996; Lee and Longnecker,
1997). BJAB cells reacted with monoclonal antibody L2 reactive with EBV gp110 (A) or BJAB cells reacted with monoclonal antibody II105-1 reactive
with HSV-1 gB (B). Plasmids used in each transfection are indicated and whether live or fixed cell preparations were stained as previously described
(Lee and Longnecker, 1997).
1991). K082 was derived from HSV-1(KOS) and contains that infection of Vero cells with K082 virus produces very
low titers of virus when assayed on gB expressing cells.a nonsense mutation at codon 43 of gB (Cai et al., 1987).
It produces no detectable gB and can only be propagated In contrast, when a plasmid able to complement the gB
defect is first transfected into the Vero cells, the amounton a gB producing cell line like Vero-B24 (Cai et al., 1987;
Herold et al., 1991). Previous studies had demonstrated of infectious virus produced is at least two orders of
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TABLE 3
Transformants Obtained by Passage of EBV(gp110/)/ and EBV(gp1100)/ LCLs by Complementation with gB-gp110 Chimeras a
pgBHSV(1–722) pgBHSV(1–788)
Experimental group Cell line pSVgp110 (EBV(680–857) EBV(746–857)
EBV(gp110/)/ LCLs (Cocultivation) LCL10 57 59 54
36 20 33
96 96 96
96 96 96
93 93 96
Total 378 364 375
EBV(gp110/)/ LCLs (Cell free) LCL1 1 2 2
LCL10 5 5 4
92 82 75
Total 98 89 81
EBV(gp1100)/ LCLs (Cocultivation) M.2 1 0 0
M.2 10 0 0
M.2 9 0 0
M.2 6 0 0
M.2 6 0 0
KC.1 3 0 0
Total 35 0 0
EBV(gp1100)/ LCLs (Cell free) M.2 1 0 0
M.2 2 0 0
M.2 3 0 0
M.2 11 0 0
Total 17 0 0
a Cells were transfected with the indicated plasmids. Three to five days posttransfection, primary human B lymphocytes were cocultivated with
gamma-irradiated transfected cells or infected with cell-free virus. Wells positive for EBV transformation were counted 6–8 weeks after the infection.
One 96-well plate was used for each transfection. Each line represents a different experiment. Totals represent the sum of the number of clones
that emerged for each experimental group as indicated. The presence of the SVHYG insertion in the newly obtained LCLs from EBV(gp1100)/
LCLs was verified by PCR (data not shown) as previously described (Herrold et al., 1996). Control amplifications for the EBV genome using primers
specific for the BHRF1 gene (Marchini et al., 1991) as expected were positive for all EBV/ LCLs (data not shown).
magnitude greater than vector control-transfected Vero plement the gB mutation in K082 (Mettenleiter and Spear,
1994).cells. Using this complementation system, the ability of
EBV gp110, HCMV gB, previously described gp110 tail Vero cells were transfected with each of the glycopro-
tein expression vectors (Table 4) and expression wasdeletion mutants, and the gp110-gB chimeric proteins to
complement the gB defect in K082 virus was investi- verified by fixing the cells 16 to 18 hr posttransfection.
Following fixation, the cells were reacted with either thegated. The three previously described gp110 tail domain
truncation mutants lack 16 (pDM(1-841)), 41 (pDM(1- EBV gp110-specific monoclonal antibody L2 (Fig. 4, EBV
gp110), the HSV-1 gB-specific antibody II105-1 (Fig. 4,816)), or 56 (pDM(1-801)) amino acids from the carboxyl-
terminal tail domain of gp110 (Lee and Longnecker, HSV-1 gB), or the HCMV gB-specific antibody 27-78 (Fig.
4, HCMV gB). Following primary antibody treatment, the1997). None of the gp110 tail domain truncation mutants
were able to complement EBV(gp1100)/ LCLS, but cells were treated with biotinylated goat-anti-mouse, fol-
lowed by streptavidin-b-galactosidase conjugate, andsince 41 amino acids can be deleted from HSV-1 gB
without affecting the function of gB, it was of interest to stained for b-galactosidase activity with X-Gal. Each of
the glycoprotein expression constructs were expresseddetermine if gp110 or any of the gp110 deletion mutants
could complement the K082 virus. The truncation mutant to similar levels as determined by this method (Fig. 4).
Duplicate dishes also transfected with the glycoproteinpDM(1–816) was of particular interest. It along with
pDM(1–801) were readily detected in both fixed and live constructs were infected with K082 virus. One day follow-
ing infection, the resulting progeny virus was titered oncell immunofluorescence similar to HSV-1 gB, whereas
pDM(1-841) was detected only in fixed cell immunofluo- both Vero and Vero-B24 cells (Table 4, Vero-B24 or Vero).
The ratio between the two titers is also shown (Table 4,rescence like wild-type gp110 (Lee and Longnecker,
1997). A previously described expression vector pMT-gII Vero-B24/Vero). Vero cells transfected the with HSV-1 gB
expression vector pHSV-gB or the PrV gB expressionfor PrV gB and pHSV-gB were included as controls. PrV
gB and HSV-1 gB were previously demonstrated to com- vector pMT-gII were able to complement the gB mutation
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TABLE 4 degree of conservation of gB function. BHV-1 gB can
complement for PrV gB in the PrV virus background (KoppTiters of Viral Stocks on Vero-B24 or Vero Cells Prepared by Infec-
and Mettenleiter, 1992; Rauh et al., 1991). In contrast ation of Vero Cells Transfected with the Glycoprotein Expression Vec-
tors a BHV-1 gB null mutant is unable to be complemented by
PrV gB (Miethke et al., 1995). Using chimeric gB proteins
Plasmid Vero-B24 Titer Vero Titer VgB/Vero between PrV gB and BHV-1 gB, the carboxy-terminal por-
tion of BHV-1 gB was demonstrated to be important forpSG5 30 280 0.1
BHV-1 gB-specific function (Miethke et al., 1995). PrV gBpHSV-gB 77000 260 296.2
pSVgp110 (EBV) 230 210 1.1 is able to substitute for gB in HSV-1 (Mettenleiter and
pHCMV-gB 30 130 0.2 Spear, 1994), but HSV-1 gB is not able to complement
pMT-gII (PRV) 28000 100 280 PrV gB null viruses (Mettenleiter and Spear, 1994) and
pDM(1-841) (EBV) 10 10 10
the gB of varicella-zoster virus appears to be deficientpDM(1-816) (EBV) 10 10 10
in complementation of HSV-1 null mutants (Felser et al.,pDM(1-801) (EBV) 110 160 0.7
pgBHSV(1-722)EBV(680-857) 10 10 10 1987).
pgBHSV(1-788)EBV(746-857) 50 110 0.5 To investigate conserved functional roles between the
human a-herpesvirus, b-herpesvirus, and g-herpesvirusa Vero cells were transfected with the indicated plasmids. 16–18 hr
subfamilies, complementation studies were performedposttransfection the transfected cells were infected with K082. 24 hr
using a HSV-1 gB null virus and a EBV gp110 null virus.postinfection virus stocks were prepared and titered on either Vero
cells or gB-expressing B24 cells and were expressed as PFU/ml. In these studies, neither HCMV gB nor HSV-1 gB was
able to complement a gp110 null mutation in EBV. In
addition, neither HCMV gB nor EBV gp110 was able to
in K082 virus (Table 4). This is in good agreement with
complement a gB null mutation in HSV-1.
prior results demonstrating that HSV-1 gB and PrV gB
Chimeric HSV-1 gB and EBV gp110 proteins were also
are able to complement the gB mutation in K082 virus
tested in complementation assays. One chimeric protein
(Cai et al., 1987; Mettenleiter and Spear, 1994). In con-
contained the ectodomain and first two and two-thirds
strast, EBV gp110 or HCMV gB were unable to comple-
of the three gB hydrophobic domains fused to the last
ment the K082 gB mutation. In addition, none of the pre-
one-third of the final hydrophobic domain and tail domain
viously described EBV gp110 tail deletion mutations or
of gp110. The other chimeric construct contained the
the gB-gp110 chimeric proteins were able to complement
ectodomain of HSV-1 gB fused to the three hydrophobic
the K082 mutation. These experiments were repeated
domains and tail domain of EBV. Both chimeric proteins
two additional times with similar results (data not shown).
were retained in intracellular membranes similar to EBV
gp110 confirming a domain for nuclear membrane and
DISCUSSION
ER retention is located in the tail domain of gp110. Previ-
ous deletion mutagenesis studies had identified aminoThe gB gene is the most highly conserved glycoprotein
among the members of the herpesvirus family. Nucleo- acids 816 to 841 within the gp110 tail domain as essential
for nuclear membrane and ER retention (Lee and Long-tide sequence analysis has identified homologues of gB
in every human and animal herpesvirus studied to date necker, 1997). It is unlikely that this retention is due to
misfolding of the chimeric proteins. First, two separate(Goltz et al., 1994; Pereira, 1994). The EBV gp110 (Baer
et al., 1984), the HSV-1 gB (Pellett et al., 1985b), and the chimeric proteins were made which behave similarly.
Second, the pgBHSV(1–722)EBV(680–857) chimeric pro-HCMV gB (Cranage et al., 1986) proteins consist of three
domains. There is a large amino terminal ectodomain of tein was carefully constructed to contain the ectodomain
of gB with the hydrophobic domains and tail domain of685 (EBV gp110), 726 (HSV-1 gB), or 689 (HCMV gB)
amino acids; two or three hydrophobic regions spanning gp110 to preserve the individual domains of gB and
gp110 to insure proper folding. Both chimeric proteinsamino acids 686 to 753 (EBV gp110), 727 to 795 (HSV-1
gB), or 714–771 (HCMV gB); and a carboxyl terminal tail were unable to complement HSV-1 gB or EBV gp110 null
mutants, suggesting that there are multiple domains indomain of either 104 (EBV gp110), 109 (HSV-1 gB), or 125
(HCMV gB) amino acids (Chee et al., 1990; Pellett et al., the gB and gp110 that are important for function in the
respective viruses. This result is interesting in light of1985a; Spaete et al., 1988). Within the ectodomain of
all sequenced herpesviruses are 10 conserved cysteine the previous results with PrV and BHV-1 gB chimeric
proteins tested in a gB null mutant of BHV-1 (Miethke etresidues as well as 7 conserved proline residues scat-
tered throughout the different gBs (Goltz et al., 1994). al., 1995). In contrast to this study, it was shown that the
carboxy-terminal domain of BHV-1 gB when combinedThese observations indicate that the different herpesvi-
rus gBs may have similar functional roles in herpesvirus with the amino-terminal portion of PrV gB was sufficient
to complement the BHV-1 gB null mutant.infection.
Previous studies using gBs from human and animal Finally, three previously described EBV gp110 tail dele-
tion mutants which were unable to complement EBVa-herpesvirus subfamily members has indicated some
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